LYVE1 Antikörper (AA 290-318) (FITC)
Kurzübersicht für LYVE1 Antikörper (AA 290-318) (FITC) (ABIN674806)
Target
Alle LYVE1 Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
-
-
Bindungsspezifität
- AA 290-318
-
Kreuzreaktivität
- Human, Maus
-
Homologie
- Rat
-
Aufreinigung
- Purified by Protein A.
-
Immunogen
- KLH conjugated synthetic peptide derived from mouse LYVE-1
-
Isotyp
- IgG
-
-
-
-
Applikationshinweise
- IF(IHC-P) 1:50-200
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Konzentration
- 1 μg/μL
-
Buffer
- Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.
-
Konservierungsmittel
- Sodium azide
-
Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
-
Lagerung
- -20 °C
-
Informationen zur Lagerung
- Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
-
Haltbarkeit
- 12 months
-
-
- LYVE1 (Lymphatic Vessel Endothelial Hyaluronan Receptor 1 (LYVE1))
-
Andere Bezeichnung
- Lyve-1
-
Hintergrund
-
Synonyms: Xlkd1, Lyve-1, Crsbp-1, 1212G8Rik, Lymphatic vessel endothelial hyaluronic acid receptor 1, Cell surface retention sequence-binding protein 1, Extracellular link domain-containing protein 1, Lyve1, Crsbp1
Background: Ligand-specific transporter trafficking between intracellular organelles (TGN) and the plasma membrane. Plays a role in autocrine regulation of cell growth mediated by growth regulators containing cell surface retention sequence binding (CRS). May act as a hyaluronan (HA) transporter, either mediating its uptake for catabolism within lymphatic endothelial cells themselves, or its transport into the lumen of afferent lymphatic vessels for subsequent re-uptake and degradation in lymph nodes.
-
Gen-ID
- 114332
-
UniProt
- Q8BHC0
-
Pathways
- Glycosaminoglycan Metabolic Process
Target
-